Paper17526015
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.
Gary-Bobo M and 19 others. Hepatology, 2007. Cited by 247 papers, by iCite.
Cite this record
ConductScience Library. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Papers, record 17526015. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17526015
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fatty Liver | Major topic |
| Metabolic Syndrome | Major topic |
| Obesity | Major topic |
| Piperidines | Major topic |
| Pyrazoles | Major topic |
| Animals | |
| Cannabinoid Receptor Antagonists | |
| Inflammation | |
| Liver | |
| Male | |
| RNA | |
| Rats | |
| Rats, Zucker | |
| Reverse Transcriptase Polymerase Chain Reaction | |
| Rimonabant | |
| Tumor Necrosis Factor-alpha |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17596867 | Food energy efficiency, cannabinoids, and a slow death of the weight loss dogma. | https://conductscience.org/library/papers/17596867 |
Source PubMed
Cited by120
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 247 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41869774 | Acute metabolic effects of cannabinoid receptor modulators during sequential hyperglycemic, euglycemic-hyperinsulinemic clamps in healthy individuals. | Am J Physiol Endocrinol Metab | 2026 | https://conductscience.org/library/papers/41869774 | PubMed |
| 41867680 | Taurine attenuates lipid accumulation via the eCB-CB1 axis: evidence from adipose metabolomics in HFD-fed mice and 3D adipocyte spheroids. | Front Nutr | 2026 | https://conductscience.org/library/papers/41867680 | PubMed |
| 40290527 | Cannabinoids and the endocannabinoid system in liver diseases. | Clin Exp Hepatol | 2024 | https://conductscience.org/library/papers/40290527 | PubMed |
| 39941074 | The Endocannabinoid System: Implications in Gastrointestinal Physiology and Pathology. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39941074 | PubMed |
| 39296275 | Novel Peripherally Selective Cannabinoid Receptor 1 Neutral Antagonist Improves Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice. | ACS Pharmacol Transl Sci | 2024 | https://conductscience.org/library/papers/39296275 | PubMed |
| 39292202 | The endocannabinoid system in appetite regulation and treatment of obesity. | Pharmacol Res Perspect | 2024 | https://conductscience.org/library/papers/39292202 | PubMed |
| 37371762 | Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity. | Biomedicines | 2023 | https://conductscience.org/library/papers/37371762 | PubMed |
| 36442615 | Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes. | J Control Release | 2023 | https://conductscience.org/library/papers/36442615 | PubMed |
| 36329422 | Circulating endocannabinoid levels in pregnant women with gestational diabetes mellitus: a case-control study. | BMC Endocr Disord | 2022 | https://conductscience.org/library/papers/36329422 | PubMed |
| 35420457 | Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock? | Cannabis Cannabinoid Res | 2023 | https://conductscience.org/library/papers/35420457 | PubMed |
| 35328343 | Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35328343 | PubMed |
| 34754376 | Metabolic and inflammatory functions of cannabinoid receptor type 1 are differentially modulated by adiponectin. | World J Diabetes | 2021 | https://conductscience.org/library/papers/34754376 | PubMed |
| 34610720 | Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases. | Diabetes Metab J | 2021 | https://conductscience.org/library/papers/34610720 | PubMed |
| 34220518 | Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34220518 | PubMed |
| 33896380 | At the heart of microbial conversations: endocannabinoids and the microbiome in cardiometabolic risk. | Gut Microbes | 2021 | https://conductscience.org/library/papers/33896380 | PubMed |
| 33562080 | Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome. | Molecules | 2021 | https://conductscience.org/library/papers/33562080 | PubMed |
| 33138155 | Effects of the CB1 Receptor Antagonists AM6545 and AM4113 on Insulin Resistance in a High-Fructose High-Salt Rat Model of Metabolic Syndrome. | Medicina (Kaunas) | 2020 | https://conductscience.org/library/papers/33138155 | PubMed |
| 32987186 | Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent. | Mol Metab | 2020 | https://conductscience.org/library/papers/32987186 | PubMed |
| 32927872 | A Peripheral CB1R Antagonist Increases Lipolysis, Oxygen Consumption Rate, and Markers of Beiging in 3T3-L1 Adipocytes Similar to RIM, Suggesting that Central Effects Can Be Avoided. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32927872 | PubMed |
| 32798334 | Cannabinoid receptor type 1 antagonist inhibits progression of obesity-associated nonalcoholic steatohepatitis in a mouse model by remodulating immune system disturbances. | Immun Inflamm Dis | 2020 | https://conductscience.org/library/papers/32798334 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17526015
GET https://conductscience.org/api/papers/v1/17526015/cited_by?page=2